Article
Prevalence of relevant NS5A resistance-associated substitutions to elbasvir in genotype 1a hepatitis C virus patients in Spain.
Enfermedades infecciosas y microbiologia clinica (English ed.) - 1 May 2018
Palladino Claudia, Esteban-Cartelle Beatriz, Mate-Cano Irene, Sánchez-Carrillo Marta, Resino Salvador, Briz Verónica
Abstract excerpt
Resistance-associated substitutions (RASs) to the new HCV NS5A inhibitor elbasvir may limit its efficacy and lead to virological failure in HCV-GT1a-infected patients. There are no data outside clinical trials evaluating their prevalence and impact in grazoprevir/elbasvir in GT1a-infected patients in Spain. A multicentre cross-sectional study of 632 initial patients was conducted. In 13 of these patients, the...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
